Small-molecule drugs · SYK inhibitors · Autoimmune disease & blood cancer
Oscotec
A biotech developing small-molecule drugs, researching SYK inhibitors targeting autoimmune diseases and blood cancers. KOSDAQ large-cap constituent. Baseline node ahead of value-chain research; promoted to a full node once AI question demand is observed.
039200.KQ Updated Jul 11, 2026 3 AI consumers· 2 recurring
Annual return · 2026-09-04'21-17%'22-38.1%'23-0.3%'24+39.8%'25+108.2%YTD-34.2%
Money in ▸·
Oscotec
▸ Money out·
Financials & Segments
- Segments · Drug development (SYK inhibitor) · Subsidiaries
Revenue from
No refined links yet.
Pays to
No refined links yet.